熱門資訊> 正文
Vir Biotechnology宣布首席财务官转型
2026-07-24 20:39
- Vir Biotechnology (VIR) on Friday said Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed interim Principal Financial Officer, effective July 23.
- Jason O’Byrne is leaving the company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition.
- Sabatini has served as Senior Vice President and Chief Accounting Officer for Vir Biotechnology since February 2023. He has more than two decades of experience and was previously Head of Finance at Capsida Biotherapeutics. Before that, he was at Amgen Inc. from 2004 to 2021.
- Press release
More on Vir Biotechnology
- Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead
- Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
- Vir Biotechnology anticipates VIR-5500 Phase III start in 2027 while expecting cash runway into 2H 2028
- Vir Biotechnology GAAP EPS of -$0.85 misses by $0.93
推薦文章
美股前瞻 | 史詩級「軋空」來襲！比特幣升破7.2萬美元；業績股齊遇冷！沃爾瑪盤前大跌逾6%，阿里、網易均跌近4%
一圖看懂 | 泡泡瑪特上半年營收171億、淨利50億均大遜預期！星星人IP逆勢暴漲580%；王寧稱計劃半年內大額回購20-50億
Moderna暴漲177%！mRNA癌症疫苗迎來「ChatGPT時刻」？16只港美標的誰會接過下一棒？
「影子股」已暴漲90%！如何在Anthropic史上最大IPO前搶跑入局？最全攻略來了
港股異動 | 全球首個mRNA癌症疫苗三期成功落地！港股醫藥股齊衝高，康希諾生物飆升49%，雲頂新耀勁升42%
資金流向顯示億萬富豪Ken Fisher旗下機構以40億美元逆勢抄底長期美債
SK海力士出手救市！擬回購並註銷約283億美元的股票
賽力斯港股上市后首虧!半年虧掉17億,狂燒70億搞研發
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
